Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

STORY: "Studies have shown that when you go off these drugs, you tend to put the weight right back on," Coons said. "So this ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...

Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding ...

Investors were excited as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare ...

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade ...

Novo Nordisk's team in India is urging the company to launch its popular weight-loss drug, Wegovy, next year to stay ahead of ...

In a closed-door meeting at Novo's Denmark headquarters about two months ago, the India team raised concerns that the company ...